Context Therapeutics Inc (CNTX) has a current Price-to-Book (P/B) ratio of 1.95. Compared to its 3-year average P/B ratio of 1.24, the current P/B ratio is approximately 57.07% higher. Relative to its 5-year average P/B ratio of 1.00, the current P/B ratio is about 95.51% higher. Context Therapeutics Inc (CNTX) has a Forward Free Cash Flow (FCF) yield of approximately -15.72%. Compared to its 3-year average FCF yield of -57.79%, the current FCF yield is approximately -72.80% lower. Relative to its 5-year average FCF yield of -55.28%, the current FCF yield is about -71.57% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CNTX competitors is 283.54, providing a benchmark for relative valuation. Context Therapeutics Inc Corp (CNTX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CNTX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CNTX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CNTX currently overvalued or undervalued?

What is Context Therapeutics Inc (CNTX) fair value?

CNTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Context Therapeutics Inc (CNTX) is between to according to relative valuation method.

How does CNTX's valuation metrics compare to the industry average?

The average P/S ratio for CNTX's competitors is 283.54, providing a benchmark for relative valuation. Context Therapeutics Inc Corp (CNTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Context Therapeutics Inc (CNTX) as of Mar 02 2026?

As of Mar 02 2026, Context Therapeutics Inc (CNTX) has a P/B ratio of 1.95. This indicates that the market values CNTX at 1.95 times its book value.

What is the current FCF Yield for Context Therapeutics Inc (CNTX) as of Mar 02 2026?

As of Mar 02 2026, Context Therapeutics Inc (CNTX) has a FCF Yield of -15.72%. This means that for every dollar of Context Therapeutics Inc's market capitalization, the company generates -15.72 cents in free cash flow.

What is the current Forward P/E ratio for Context Therapeutics Inc (CNTX) as of Mar 02 2026?

As of Mar 02 2026, Context Therapeutics Inc (CNTX) has a Forward P/E ratio of -3.53. This means the market is willing to pay $-3.53 for every dollar of Context Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Context Therapeutics Inc (CNTX) as of Mar 02 2026?

As of Mar 02 2026, Context Therapeutics Inc (CNTX) has a Forward P/S ratio of 0.00. This means the market is valuing CNTX at $0.00 for every dollar of expected revenue over the next 12 months.

CNTX Valuation